Kiri

Tere

Edastan pöördumise.

Heade soovidega

Kärolin Jenas
Ravimiamet
arendus- ja haldusosakonna dokumendihalduse spetsialist

Telefon 737 4140
karolin.jenas@ravimiamet.ee

Nooruse 1
50411 Tartu
www.ravimiamet.ee

Selles e-kirjas sisalduv teave (kaasa arvatud manused) on mõeldud ametialaseks kasutamiseks ning seda võivad kasutada vaid e-kirja adressaadid. E-kirjas sisalduvat teavet ei tohi ilma saatja selgelt väljendatud loata edasi saata ega mis tahes viisil kolmandatele isikutele avaldada. Juhul, kui Te olete saanud käesoleva e-kirja eksituse tõttu, teavitage sellest koheselt saatjat ning kustutage e-kiri.
This e-mail and any attachments transmitted may contain confidential and privileged information.  If you are not the intended recipient, please notify the sender immediately by returning the e-mail and permanently deleting what you have received. Any dissemination or use of this information by a third person without permission is prohibited and may be illegal.

Dear Sir/ Madam,

Hope this email finds you well.

Could you please provide us the contact information (preferably email) for regulatory authority and Pharmacovigilance for Estonia.

In addition, could you please provide the following information for  post-marketing Medical device Clinical Trials in Estonia.   

Post-marketing Medical Device Clinical Trials (AGGR requirements):

• Destination (Agency Name):

• Requirements:

• Aggregate Report Type:

• Timelines:

• Translation required for Aggregate Reports in regional language ? (Yes/No)

Thanks & Regards

Sai Kiran Topa

Safety Science Analyst

E: saikiran.topa@fortrea.com

M: +91 7093615048 | fortrea.com

Fortrea
This e-mail may contain confidential, proprietary, or protected information - including protected health information - that is meant to be viewed only by the intended recipient or company. Any unauthorized review, use, copying, downloading or disclosure is strictly prohibited. If this e-mail is not intended for you, or if you have received this e-mail in error, please notify the sender immediately. Do not forward it to any further recipients and permanently delete this e-mail and all attachments. If you have questions or concerns, please see our privacy policy on Fortrea.com